-
1Report
المؤلفون: Newcastle University, University of Nottingham, University of Cambridge, University of Seville, Pinnacle Clinical Research, PLLC, ICAN Nutrition Education and Research, Assistance Publique - Hôpitaux de Paris, University of Angers, University of Palermo, University of Turin, Italy, University Medical Center Mainz, University of Helsinki, University of Bern, Linkoeping University, Perspectum, Antaros Medical, Resoundant Inc, Pfizer, Novartis, Takeda, Boehringer Ingelheim, Intercept Pharmaceuticals, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
المصدر: Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & Validation of Imaging Modality Performance Across the NAFLD Spectrum in a Prospectively Recruited Cohort
Pavlides M, Mozes FE, Akhtar S, Wonders K, Cobbold J, Tunnicliffe EM, Allison M, Godfrey EM, Aithal GP, Francis S, Romero-Gomez M, Castell J, Fernandez-Lizaranzu I, Aller R, Gonzalez RS, Agustin S, Pericas JM, Boursier J, Aube C, Ratziu V, Wagner M, Petta S, Antonucci M, Bugianesi E, Faletti R, Miele L, Geier A, Schattenberg JM, Tilman E, Ekstedt M, Lundberg P, Berzigotti A, Huber AT, Papatheodoridis G, Yki-Jarvinen H, Porthan K, Schneider MJ, Hockings P, Shumbayawonda E, Banerjee R, Pepin K, Kalutkiewicz M, Ehman RL, Trylesinksi A, Coxson HO; LITMUS Consortium Investigators; Martic M, Yunis C, Tuthill T, Bossuyt PM, Anstee QM, Neubauer S, Harrison S. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol. Contemp Clin Trials. 2023 Nov;134:107352. doi: 10.1016/j.cct.2023.107352. Epub 2023 Oct 4. -
2Electronic ResourceA cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe
المؤلفون: Universidad de Sevilla. Departamento de Medicina, Allergan Pharmaceutical International Ltd., Bristol-Myers-Squibb Company, EASL International Liver Foundation from Gilead Sciences Europe Ltd., Horizon 2020 Framework Program of the European Union, IMI2 Program of the European Union, Miguel Servet, Pfizer Inc., Resoundant Inc., Lazarus, Jeffrey V., Ekstedt, Mattias, Marchesini, Giulio, Mullen, Jillian, Novak, Katja, Pericàs, Juan M., Romero Gómez, Manuel, Anstee, Quentin M.
مصطلحات الفهرس: Europe, Guidelines as topic, Health Policy, Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH), Review, info:eu-repo/semantics/article
URL:
https://hdl.handle.net/11441/144623 https://www.sciencedirect.com/science/article/pii/S0168827819305215?via%3Dihub
Journal of Hepatology, 72 (1), 14-24.
634413
777377https://www.sciencedirect.com/science/article/pii/S0168827819305215?via%3Dihub -
3Academic JournalA cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe
المؤلفون: Lazarus, Jeffrey V., Ekstedt, Mattias, Marchesini, Giulio, Mullen, Jillian, Novak, Katja, Pericàs, Juan M., Romero Gómez, Manuel, Anstee, Quentin M.
المساهمون: Universidad de Sevilla. Departamento de Medicina, Allergan Pharmaceutical International Ltd., Bristol-Myers-Squibb Company, EASL International Liver Foundation from Gilead Sciences Europe Ltd., Horizon 2020 Framework Program of the European Union, IMI2 Program of the European Union, Miguel Servet, Pfizer Inc., Resoundant Inc.
مصطلحات موضوعية: Europe, Guidelines as topic, Health Policy, Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH), Review
Relation: Journal of Hepatology, 72 (1), 14-24.; 634413; 777377; https://www.sciencedirect.com/science/article/pii/S0168827819305215?via%3Dihub; https://idus.us.es/handle//11441/144623
-
4Academic JournalA cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe
المؤلفون: Lazarus, Jeffrey V., Ekstedt, Mattias, Marchesini, Giulio, Mullen, Jillian, Novak, Katja, Pericàs, Juan M., Roel, Elena, Romero-Gómez, Manuel, Ratziu, Vlad, Tacke, Frank, Cortez-Pinto, Helena, Anstee, Quentin M.
المساهمون: EASL International Liver Foundation, Gilead Sciences Europe Ltd., Allergan Pharmaceutical International Ltd., Bristol-Myers-Squibb Company, Pfizer Inc., Resoundant Inc., University of Barcelona, Horizon 2020 Framework Program of the European Union
المصدر: Journal of Hepatology ; volume 72, issue 1, page 14-24 ; ISSN 0168-8278